
Michael Makris
@profmakris
Emeritus Professor of Haemostasis and Thrombosis in Sheffield, UK. I tweet about thrombosis, hemophilia, COVID-19, medicine, NHS & AI. Opinions are my own.
ID: 84063737
21-10-2009 11:58:13
13,13K Tweet
13,13K Followers
1,1K Following

Using AI in Scientific Research! 👩💻 This study by Deepa_Arachchillage compares 7 different AI models to predict VTE risk in Covid-19 patients. Read more about it: rpthjournal.org/article/S2475-… #artificialintelligence #covid #thrombosis



Who cares about life expectancy?! Healthy life expectancy is what matters. Roughly speaking in richer countries you are healthy for longer. Costa Rica punches above its weight while the US ranks as a pathetic 71st. Great chart by Ruben Mathisen.




Join Cedric Hermans, MD, FRCP (Lon, Edin), PhD and Michael Makris in this E-learning Insight session as they share practical strategies and key considerations to help you navigate the world of scientific publishing. Learn how to write with purpose and make your research stand out.📺 academy.eahad.org/eahad/2023/e-l…




Any idea of the price of this, Brian O Mahony? Presumably there is nothing to stop patients from traveling to China to have it. It is difficult to believe it will cost anything remotely close to Hemgenix.



Thank you for the copies of the paper on the UK Infected Blood Inquiry that was published in Blood Journal. It is interesting to see the section on lessons learned. Despite the Infected Blood Inquiry, the UK continues to use cryo and FFP without viral inactivation. #hemophilia


Michael Makris Blood Journal Infected Blood Inquiry This is true in the USA. Not used routinely in healthy young patients with coagulation disorders. Mostly in critically ill patients with rather dismal prognoses for what it’s worth. Costs are much higher and general consensus is risks of known blood borne pathogens low. Until not






Thank you Michael Makris for your clear and concise commentary on our #PITT case in British Journal of Haematology. Take home message: test anyone with the combination of thrombosis and thrombocytopenia for anti-PF4 antibodies (by ELISA) and have a low threshold for starting non-heparin anticoagulation
